FILE PHOTO: A nurse draws from a vial of Johnson & Johnson coronavirus disease (COVID-19) vaccine, in Los Angeles, California, U.S., March 25, 2021. REUTERS/Lucy Nicholson/File Photo
Johnson & Johnson’s (J&J) manufacturing partner Emergent Biosolutions said on Thursday that it had disposed of the single batch of COVID-19 drug substance that did not meet specifications.
J&J on Wednesday said it had found a problem with a batch of the drug substance for its COVID-19 vaccine being produced at Emergent’s site in Baltimore, Maryland.
“Discarding a batch of bulk drug substance, while disappointing, does occasionally happen during vaccine manufacturing, which is a complex and multi-step biological process”, Emergent said.
MOST READ
LATEST STORIES